PALCICLIB 125 CAPSULES

Product Description

PALCICLIB 125 CAPSULES is a premium oncology product containing Palbociclib 125mg, a targeted CDK4/6 inhibitor widely prescribed in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Formulated to meet international quality standards, this oral chemotherapy capsule is designed for precision cancer therapy with enhanced patient outcomes.

Trusted by leading oncologists, PALCICLIB 125 is ideal for pharmaceutical distributors, hospital suppliers, cancer care centers, and bulk medicine buyers seeking reliable, high-efficacy cancer drugs.

Key Benefits:

• Contains Palbociclib 125mg, a proven CDK4/6 inhibitor for breast cancer

• Enables targeted therapy with better tolerability and prolonged progression-free survival

• Manufactured in GMP-certified facilities ensuring global quality compliance

• Attractive bulk pricing for large-scale procurement

Usage:

• Indicated in combination with hormonal therapies such as Letrozole or Fulvestrant

• Used in first-line and second-line treatment of metastatic breast cancer

• Prescribed in oncology departments and specialty clinics

Why Choose PALCICLIB 125 CAPSULES?

• Trusted active molecule in advanced breast cancer management

• Excellent choice for bulk exporters, hospital tender suppliers, and medical wholesalers

• Consistent availability with prompt nationwide delivery